TC BioPharm Ownership
| TCBP Stock | USD 0.50 1.04 67.53% |
TCBP |
TCBP Stock Ownership Analysis
The company has price-to-book ratio of 0.32. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. TC BioPharm Holdings recorded a loss per share of 192.95. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 5th of August 2024. TC Biopharm Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Tc Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. To find out more about TC BioPharm Holdings contact Bryan Kobel at 44 14 1433 7557 or learn more at https://tcbiopharm.com.Besides selling stocks to institutional investors, TC BioPharm also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different TC BioPharm's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align TC BioPharm's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
TC BioPharm Quarterly Liabilities And Stockholders Equity |
|
TCBP Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as TC BioPharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TC BioPharm Holdings backward and forwards among themselves. TC BioPharm's institutional investor refers to the entity that pools money to purchase TC BioPharm's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | Platform Technology Partners | 2024-09-30 | 0.0 | Sbi Securities Co Ltd | 2024-12-31 | 4.1 K | Gamma Investing Llc | 2024-12-31 | 1.2 K | Rhumbline Advisers | 2024-12-31 | 1.1 K | Harbour Investments, Inc. | 2024-12-31 | 236 | New England Capital Financial Advisors Llc | 2024-12-31 | 201 | Toth Financial Advisory Corp | 2024-12-31 | 30.0 | Signaturefd, Llc | 2024-12-31 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Sanctuary Wealth Management, Llc | 2024-12-31 | 0.0 |
TC BioPharm Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TC BioPharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on TC BioPharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TC BioPharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Randall Mark Edward over two weeks ago Acquisition by Randall Mark Edward of 70000 shares of TC BioPharm subject to Rule 16b-3 | ||
Randall Diana Elizabeth over a month ago Acquisition by Randall Diana Elizabeth of 70000 shares of TC BioPharm subject to Rule 16b-3 | ||
Randall Kenneth Edward over a month ago Discretionary transaction by Randall Kenneth Edward of 5306464 shares of TC BioPharm at 4.25 subject to Rule 16b-3 | ||
Randall Mark Edward over six months ago Acquisition by Randall Mark Edward of 70000 shares of TC BioPharm subject to Rule 16b-3 |
TC BioPharm Outstanding Bonds
TC BioPharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. TC BioPharm Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most TCBP bonds can be classified according to their maturity, which is the date when TC BioPharm Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US878091BD86 Corp BondUS878091BD86 | View | |
| US878091BG18 Corp BondUS878091BG18 | View | |
| US878091BF35 Corp BondUS878091BF35 | View | |
| US878091BC04 Corp BondUS878091BC04 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Pair Trading with TC BioPharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.Moving together with TCBP Stock
Moving against TCBP Stock
| 0.91 | FNA | Paragon 28 | PairCorr |
| 0.9 | CPIX | Cumberland Pharmaceuticals | PairCorr |
| 0.78 | CMRX | Chimerix | PairCorr |
| 0.42 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.
The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.